183 related articles for article (PubMed ID: 6247064)
1. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum(II) by WR-2721 without altering its antitumor properties.
Yuhas JM; Culo F
Cancer Treat Rep; 1980 Jan; 64(1):57-64. PubMed ID: 6247064
[TBL] [Abstract][Full Text] [Related]
2. Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
Milas L; Ito H; Hunter N
Cancer Res; 1983 Jul; 43(7):3050-6. PubMed ID: 6303574
[TBL] [Abstract][Full Text] [Related]
3. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine.
Yuhas JM
Cancer Treat Rep; 1979 Jun; 63(6):971-6. PubMed ID: 223759
[TBL] [Abstract][Full Text] [Related]
4. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Treskes M; Boven E; Holwerda U; Pinedo HM; van der Vijgh WJ
Cancer Res; 1992 Apr; 52(8):2257-60. PubMed ID: 1313740
[TBL] [Abstract][Full Text] [Related]
5. cis-Dichlorodiammineplatinum nephrotoxicity in rats of different ages.
Braunlich H; Kuo CH; Slocombe R; Hook JB
Res Commun Chem Pathol Pharmacol; 1984 May; 44(2):279-91. PubMed ID: 6539942
[TBL] [Abstract][Full Text] [Related]
6. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
7. Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen.
Baldew GS; McVie JG; van der Valk MA; Los G; de Goeij JJ; Vermeulen NP
Cancer Res; 1990 Nov; 50(21):7031-6. PubMed ID: 2208170
[TBL] [Abstract][Full Text] [Related]
8. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.
Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI
Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784
[TBL] [Abstract][Full Text] [Related]
9. Radioprotective and hemodynamic effects of WR-2721 and cystamine in rats: time course studies.
Kuna P; Volenec K; Vodicka I; Dostál M
Neoplasma; 1983; 30(3):349-57. PubMed ID: 6306492
[TBL] [Abstract][Full Text] [Related]
10. Modulation of cis-platinum renal toxicity by the radioprotective agent WR 2721.
Jordan SW; Yuhas JM; Glick J
Exp Mol Pathol; 1982 Jun; 36(3):297-305. PubMed ID: 6282619
[No Abstract] [Full Text] [Related]
11. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
[TBL] [Abstract][Full Text] [Related]
12. [Reduction of cisplatin toxicity by fosfomycin in animal models].
Ohtani I; Ohtsuki K; Aikawa T; Sato Y; Anzai T; Ouchi J; Saito T
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2400-7. PubMed ID: 6541892
[TBL] [Abstract][Full Text] [Related]
13. [Nephrotoxicity mechanisms of the antitumor preparation, cis-dichlorodiammineplatinum].
Belkin AL; Sidorik OA; Pendrak KA; Povzhitkova MS; Osadchaia LP
Vopr Onkol; 1979; 25(8):95-6. PubMed ID: 483710
[No Abstract] [Full Text] [Related]
14. Inhibition of reduction in the testicular weight by WR-2721 in relation to the body weight after whole-body gamma irradiation.
Bhartiya HC; Jaimala
Strahlenther Onkol; 1986 Jan; 162(1):68-70. PubMed ID: 3003944
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of WR-151327: an orally active chemotherapy protector.
Green D; Bensely D; Schein P
Cancer Res; 1994 Feb; 54(3):738-41. PubMed ID: 8306335
[TBL] [Abstract][Full Text] [Related]
16. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing.
Levi FA; Hrushesky WJ; Blomquist CH; Lakatua DJ; Haus E; Halberg F; Kennedy BJ
Cancer Res; 1982 Mar; 42(3):950-5. PubMed ID: 7199382
[TBL] [Abstract][Full Text] [Related]
17. 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats.
Tikoo K; Ali IY; Gupta J; Gupta C
Toxicol Lett; 2009 Dec; 191(2-3):158-66. PubMed ID: 19723570
[TBL] [Abstract][Full Text] [Related]
18. Protection from radiation nephropathy by WR-2721.
Donaldson SS; Moskowitz PS; Evans JW; Fajardo LF
Radiat Res; 1984 Feb; 97(2):414-23. PubMed ID: 6320252
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
[TBL] [Abstract][Full Text] [Related]
20. Acute and chronic cisplatin nephropathy in rats.
Choie DD; Longnecker DS; del Campo AA
Lab Invest; 1981 May; 44(5):397-402. PubMed ID: 7194946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
